Mind Medicine (MindMed) I... (MNMD)
NASDAQ: MNMD
· Real-Time Price · USD
7.37
-0.23 (-3.03%)
At close: May 21, 2025, 11:11 AM
-3.03% (1D)
| Bid | 7.34 |
| Market Cap | 556.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -77.63M |
| EPS (ttm) | -0.75 |
| PE Ratio (ttm) | -9.82 |
| Forward PE | -4.68 |
| Analyst | Buy |
| Ask | 7.38 |
| Volume | 402,879 |
| Avg. Volume (20D) | 1,275,732 |
| Open | 7.45 |
| Previous Close | 7.60 |
| Day's Range | 7.14 - 7.52 |
| 52-Week Range | 4.70 - 10.44 |
| Beta | 2.83 |
About MNMD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MNMD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MNMD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts22 hours ago
+8.42%
Mind Medicine and Compass Pathways shares are trad...
Unlock content with
Pro Subscription
3 months ago
+7.68%
Mind Medicine shares are trading higher after Evercore ISI Group initiated coverage on the stock with an Outperform rating and announced a $23 price target.
3 weeks ago · businesswire.com
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...
2 months ago · seekingalpha.com
Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call TranscriptMind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin...
